Journal of Multiple Sclerosis
ISSN - 2376-0389NLM - 101654564
Chiranjeev Bisht* and Dakshita Mehra
Multiple Sclerosis (MS) is a chronic autoimmune disease of the central nervous system, characterized by inflammation, demyelination, and axonal damage. Its exact cause remains elusive, but a combination of genetic and environmental factors triggers immune dysregulation, leading to myelin destruction and neurological deficits. MS presents with diverse clinical features, including fatigue, weakness, numbness, visual disturbances, and cognitive impairment. Diagnosed via MRI scans, the disease course can be relapsing-remitting or progressive. Disease-Modifying Therapies (DMTs) and symptomatic management are key treatment approaches. Traditional DMTs, monoclonal antibodies, and emerging therapies hold promise in halting disease progression and promoting functional recovery. Early diagnosis and comprehensive management are crucial for improving patient outcomes and quality of life. Ongoing research may lead to more effective, personalized treatments in the future
